目的 探讨红花注射液联合西洛他唑片治疗急性缺血性脑梗死的临床疗效。方法 选取2010年3月—2015年3月在中南大学湘雅医院接受治疗的急性缺血性脑梗死患者82例，根据治疗方案的差别分为对照组和治疗组，每组各41例。对照组口服西洛他唑片，100 mg/次，2次/d。治疗组在对照组基础上静脉滴注红花注射液，15 mL加入到10%葡萄糖注射液250 mL中，1次/d。两组患者均治疗2周。观察两组的临床疗效，比较两组的血清学指标和美国国立卫生研究院卒中量表（NIHSS）评分。结果 治疗后，对照组和治疗组的总有效率分别为80.49%、97.56%，两组比较差异有统计学意义（P < 0.05）。治疗后，两组血清白细胞介素-6（IL-6）、血红素氧合酶1（HO1）和N末端脑钠肽原（NT-proBNP）水平明显降低，而血管内皮生长因子（VEGF）、胰岛素样生长因子-1（IGF-1）和转化生长因子-β₁（TGF-β₁）水平明显增高，同组治疗前后比较差异有统计学意义（P < 0.05）；且治疗组这些观察指标的改善程度明显优于对照组，两组比较差异具有统计学意义（P < 0.05）。治疗后，两组NIHSS评分均明显下降，同组治疗前后比较差异有统计学意义（P < 0.05）；且治疗组NIHSS评分的下降程度明显优于对照组，两组比较差异具有统计学意义（P < 0.05）。结论 红花注射液联合西洛他唑片治疗急性缺血性脑梗死具有较好的临床疗效，可改善神经功能，调节血清学指标，安全性较好，具有一定的临床推广应用价值。

Objective To observe the clinical effect of Safflower Injection combined with Cilostazol Tablets in treatment of acute ischemic cerebral infarction. Methods Patients (82 cases) with acute ischemic cerebral infarction in Xiangya Hospital Central South University from March 2010 to March 2015 were enrolled in this study. According to the difference treatment plan, patients were divided into control and treatment groups, and each group had 41 cases. Patients in the control group were po administered with Cilostazol Tablets, 100 mg/time, twice daily. Patients in the treatment group were iv administered with Safflower Injection on the basis of the control group, 15 mL added into 10% glucose solution 250 mL, once daily. Patients in two groups were treated for two weeks. After treatment, the clinical efficacies were evaluated, and serological indexes and NIHSS scores in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.49% and 97.56%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of IL-6, HO1, and NT-proBNP in two groups were significantly decreased, but the levels of VEGF, IGF-1, and TGF-β₁ in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the NIHSS scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the NIHSS score in the treatment group were significantly lower than that in the control group, with significant difference between two groups (P < 0.05). Conclusion Safflower Injection combined with Cilostazol Tablets has clinical curative effect in treatment of acute ischemic cerebral infarction, can improve nerve function, and regulate serological indexes, with good safety, which has a certain clinical application value.